Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis
Open Access
- 27 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 55 (1) , 129-138
Abstract
Patients with cervical cancer diagnosed with a para-aortic lymph node (PALN) metastasis by computed tomography (CT) scan were analyzed to identify associated prognostic factors. A total of 55 patients were reviewed, and 27 of these patients underwent extended-field radiotherapy (EFRT). The median PALN dose in patients receiving EFRT was 45 Gy (range, 27–57.6 Gy). Of the 55 patients, 28 underwent pelvic radiotherapy (RT); concurrent chemoradiotherapy (CCRT) was administered to 41 patients. The Kaplan–Meier method was used to calculate the actuarial rate. Multivariate analysis was performed using the Cox proportional hazards model. Five-year overall survival (OS) rates were 41% and 17.9% in patients undergoing EFRT and pelvic RT (P = 0.030), respectively. Age < 53 years (P = 0.023), FIGO Stage I–II (P = 0.002), and treatment with EFRT (P = 0.003) were independent predictors of better OS. The use of CCRT (P = 0.014), Stage I–II (P = 0.002), and treatment using EFRT (P = 0.036) were independent predictors of distant metastasis. In patients undergoing EFRT plus CCRT, the 5-year OS was 50%. Three-year PALN disease-free rates were 8.8%, 57.9% and 100% (P < 0.001) in CCRT patients who received PALN doses of 0 Gy, ≤45 Gy and ≥50.4 Gy, respectively. Although PALN metastasis is thought to be distant metastasis in cervical cancer, EFRT plus CCRT shows a good outcome, particularly in younger patients in an early FIGO stage. Cervical cancer with a PALN metastasis should not be considered incurable. Doses ≥50.4 Gy for treating PALN may result in better disease control.Keywords
This publication has 44 references indexed in Scilit:
- Retrospective Analysis of Concomitant Cisplatin During Radiation in Patients Aged 55 Years or Older for Treatment of Advanced Cervical Cancer: A Gynecologic Oncology Group StudyInternational Journal of Gynecological Cancer, 2009
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2009
- A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: A gynecologic oncology group studyGynecologic Oncology, 2009
- Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized TrialsJournal of Clinical Oncology, 2008
- Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma?Gynecologic Oncology, 2007
- Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomyActa Obstetricia et Gynecologica Scandinavica, 2002
- A Comparison of Prognoses of Pathologic Stage Ib Adenocarcinoma and Squamous Cell Carcinoma of the Uterine CervixGynecologic Oncology, 2000
- Pretreatment surgical staging of patients with cervical carcinomaCancer, 1998
- Preoperative CT study of lymph nodes in cervical cancer—Its correlation with histological findingsGynecologic Oncology, 1989
- Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodesGynecologic Oncology, 1984